Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05342805
Other study ID # 16/GCN-HDDD 2022
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 3, 2022
Est. completion date August 30, 2024

Study information

Verified date April 2022
Source University Medical Center Ho Chi Minh City (UMC)
Contact Long D Vo, MD, PhD
Phone +84. 918 133 915
Email long.vd@umc.edu.vn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently, both the subtotal stomach and narrow gastric tube approaches are widely used for esophagogastric anastomosis after esophagectomy. Some stud- ies have concluded that the subtotal gastric conduit is superior to the wide gastric-tube approach, as it provides better protection of the submucosal vessels and can slightly increase gastric capacity. Furthermore, blood perfusion significantly decreases after tubular gastric surgery.


Description:

Stomach is the most common esophageal subtitute after a esophagectomy procedure, because it has a abundant blood supply and the need for only one anastomosis. However, cervical esophago-gastro anastomosis still has a high risk of complications, especially anastomosis leakage (11.9 - 25 % ). There are three types of gastric subtitute: whole stomach, subtotal stomach and narrow gastric tube. While whole stomach and subtotal stomach has an advantage in the submucosal vascular network, a narrow tube is excellent elasticity and the ease with which it can be pulled up into the neck without tension, that could affect leakage rate. On the other hand, after esophagectomy, nutrition status and quality of life (QoL) had decreased due to effect of adjuvant therapy, lower quantity of food intake, gastro-esophageal reflux and other postoperative syndromes. Several studies had shown the affect of the width of gastric tube to the postoperative nutrition and QoL, however, the results were not homogenous. This study aims to compared two types of gastric subtitute after esophagectomy: subtotal stomach and narrow gastric tube


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date August 30, 2024
Est. primary completion date April 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Pathologic finding by esophageal endoscopy: confirmed esophageal cancer. - Indication for esophagectomy - Age: 18 - 80 year old - Tumor located at the middle or lower third of the esophagus - ASA score: = 3 - Informed consent patients (explanation about our clinical trials is provided to the patients or patrons, if patient is not available) Exclusion Criteria: - Concurrent cancer or patient who was treated due to other cancer before the patient was diagnosed esophageal cancer - Pregnant patient - Using colon or intesinal conduit

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Narrow gastric tube
At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler

Locations

Country Name City State
Vietnam University Medical Center Ho Chi Minh City Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Ho Chi Minh City (UMC)

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Early complications (30-day complications): rate of anastomotic leakage Comparison of the rate of anastomotic leakage. All complications will be classified according to the Clavien-Dindo classification. 30 days after surgery
Primary Early complications (30-day complications): rate of anastomotic stricture Comparison of the rate of anastomotic stricture. All complications will be classified according to the Clavien-Dindo classification. 30 days after surgery
Primary Early complications (30-day complications): rate of bleeding Comparison of the rate of bleeding. All complications will be classified according to the Clavien-Dindo classification. 30 days after surgery
Primary Early complications (30-day complications): rate of pneumonia Comparison of the rate of pneumonia. All complications will be classified according to the Clavien-Dindo classification. 30 days after surgery
Primary Early complications (30-day complications): rate of mortality. Comparison of the rate of anastomotic leakage. All complications will be classified according to the Clavien-Dindo classification. 30 days after surgery
Primary Early complications (30-day complications): rate of reoperation. Comparison of the rate of reoperation. All complications will be classified according to the Clavien-Dindo classification. 30 days after surgery
Primary Early outcomes (30-day post operative): length of hospital stay. Comparison of the length of hospital stay. 30 days after surgery
Primary Early outcomes (30-day post operative): day of oral intake. Comparison of the day of oral intake. 30 days after surgery
Secondary Postoperative nutritional status: body weight Comparison of body weight at 6, 12 months and every year after surgery 6, 12 months and 1 year after surgery
Secondary Postoperative nutritional status: serum total protein Comparison of serum total protein at 6, 12 months and every year after surgery 6, 12 months and 1 year after surgery
Secondary Postoperative nutritional status: albumin level Comparison of albumin level at 6, 12 months and every year after surgery 6, 12 months and 1 year after surgery
Secondary Postoperative nutritional status: hemoglobin Comparison of hemoglobin at 6, 12 months and every year after surgery 6, 12 months and 1 year after surgery
Secondary Reflux esophagitis Reflux esophagitis will be evaluated using the Los Angeles classification at 6, 12 months and every year after surgery 6, 12 months and 1 year after surgery
Secondary Residue Gastritis Bile RGB (Residue Gastritis Bile) classification will be used to evaluate status of remnant stomach 6 to 12 months after surgery 6, 12 months and 1 year after
Secondary Patients' health-related quality of life Patients' health-related quality of life will be evaluated using GSRS (Gastrointestinal Symptom Rating Scale) score at 6, 12 months and every year after surgery 6, 12 months and 1 year after
Secondary Late complications: anastomotic stricture Comparison of the rate anastomotic stricture complications during the follow-up period 6, 12 months and 1 year after
Secondary Late complications: anastomotic ulcer Comparison of anastomotic ulcer during the follow-up period 6, 12 months and 1 year after
Secondary Others late complications Comparison of other late complications during the follow-up period 6, 12 months and 1 year after
Secondary Oncological outcomes: overall survival rate Comparison of overall survival rate during the follow-up period 6, 12 months and 1 year after
Secondary Oncological outcomes: rate of death due to the cancer Comparison of rate of death due to the cancer, and death from all causes during the follow-up period 6, 12 months and 1 year after
Secondary Oncological outcomes: recurrence, metastasis Comparison of recurrence, metastasis during the follow-up period 6, 12 months and 1 year after
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02544737 - Apatinib for Metastatic Esophageal Cancer. Phase 2